<DOC>
	<DOCNO>NCT00988091</DOCNO>
	<brief_summary>Subjects chronic osteoarthritis knee assign receive injection either 1.2 % sodium hyaluronate buffer saline evaluate effectiveness safety 26 week . After 26 week , subject elect receive second injection 1.2 % sodium hyaluronate follow another 26 week .</brief_summary>
	<brief_title>Investigation 1.2 % Sodium Hyaluronate Treatment Painful Chronic Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Chronic osteoarthritis ( OA ) target knee confirm American College Rheumatology ( ACR ) Criteria . Pain due OA target knee present least 6 month . During Screening Baseline visit , subject require visual analog scale ( VAS ) score ( 100 mm ) ≥ 41 mm ≤ 90 mm , record immediately follow 50foot walk , AND Baseline , decrease &gt; 10mm ( improvement ) Screening . A bilateral standing anteroposterior ( AP ) Xray confirm OA target knee . Ability willingness use acetaminophen analgesic ( rescue ) study medication Ability perform procedure require pain index evaluation ( unassisted walk 50 foot flat surface go stair ) . Willingness ability complete efficacy safety questionnaires ability read understand study instruction . Signed Subject Informed Consent Form Any major injury ( include sport injury ) target knee within prior 12 month . Any surgery target knee , hip contralateral hip within prior 12 month . Major minor articular procedure Inflammatory arthropathy rheumatoid arthritis , lupus arthropathy , psoriatic arthritis . Gout calcium pyrophosphate ( pseudogout ) diseases target knee flare within previous 6 month . Xray finding acute fracture , severe loss bone density , avascular necrosis , and/or severe bone joint deformity target knee . Osteonecrosis either knee . Fibromyalgia , pes anserine bursitis , lumbar radiculopathy , and/or neurogenic vascular claudication . Significant anterior knee pain due diagnose isolated patellafemoral syndrome chondromalacia target knee . Significant target knee joint infection skin disorder/infection within previous 6 month prior study enrollment . Symptomatic OA hip , spine , ankle , would interfere evaluation target knee . Known hypersensitivity acetaminophen , sodium hyaluronate , phosphate buffer saline solution . Women childbearing potential pregnant , nursing , plan become pregnant , agree remain acceptable method birth control throughout entire study period . Recurrent medical history severe allergic immunemediated reaction immune disorder . Vascular insufficiency lower limbs peripheral neuropathy severe enough interfere study evaluation . Current treatment treatment within previous 2 year prior Screening malignancy unless specific write permission provide Sponsor ( exclude basal cell squamous cell carcinoma skin ) . Chronic liver disease active liver disease base liver profile aspartate aminotransferase ( AST ) , alanine transaminase ( ALT ) , conjugate bilirubin &gt; 2 time upper limit normal . Renal insufficiency base serum creatinine &gt; 2.0 mg/dL . Any clinically significant laboratory value base clinical history Investigator feel may affect study evaluation . Any intercurrent chronic disease condition may interfere completion 6month ( 12month ) followup study , liver disease , severe coronary disease , drug abuse , disorder mental state , clinically significant condition . Current alcoholism , and/or know current addiction pain medication . Any clinically significant find would place patient health risk , impact study , affect completion study . Any psychiatric illness would prevent comprehension detail nature study . Participation experimental device study within 6 month prior Screening , experimental drug study within 1 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>